Treating cancer with combinations of drugs can be more effective than using a single drug.

However, figuring out the optimal combination of drugs, and making sure that all of the drugs reach the right place, can be challenging.

To help address those challenges, MIT chemists have designed a bottlebrush-shaped nanoparticle that can be loaded with multiple drugs, in ratios that can be easily controlled.

Using these particles, the researchers were able to calculate and then deliver the optimal ratio of three cancer drugs used to treat multiple myeloma.

“There’s a lot of interest in finding synergistic combination therapies for cancer, meaning that they leverage some underlying mechanism of the cancer cell that allows them to kill more effectively, but oftentimes we don’t know what that right ratio will be,” says Jeremiah Johnson, an MIT professor of chemistry and one of the senior authors of the study.

In a study of mice, the researchers showed that nanoparticles carrying three drugs in the synergistic ratio they identified shrank tumours much more than when the three drugs were given at the same ratio but untethered to a particle.

This nanoparticle platform could potentially be deployed to deliver drug combinations against a variety of cancers, the researchers say.

Irene Ghobrial, a professor of medicine at Harvard Medical School and Dana-Farber Cancer Institute, and P Peter Ghoroghchian, president of Ceptur Therapeutics and a former MIT Koch Institute Clinical Investigator, are also senior authors of the paper, which appears in Nature Nanotechnology.

Alexandre Detappe, an assistant professor at the Strasbourg Europe Cancer Institute, and Hung Nguyen PhD ’19 are the paper’s lead authors.

Using nanoparticles to deliver cancer drugs allows the drugs to accumulate at the tumour site and reduces toxic side effects because the particles protect the drugs from being released prematurely.

However, only a handful of nanoparticle drug formulations have received FDA approval to treat cancer, and only one of these particles carries more than one drug.

For several years, Johnson’s lab has been working on polymer nanoparticles designed to carry multiple drugs.

In the new study, the research team focused on a bottlebrush-shaped particle.

To make the particles, drug molecules are inactivated by binding to polymer building blocks and then mixed together in a specific ratio for polymerisation.

This forms chains that extend from a central backbone, giving the molecule a bottlebrush-like structure with inactivated drugs — prodrugs — along the bottlebrush backbone.

Cleavage of the linker that holds the drug to the backbone release the active agent.  

“If we want to make a bottlebrush that has two drugs or three drugs or any number of drugs in it, we simply need to synthesise those different drug conjugated monomers, mix them together, and polymerise them. The resulting bottlebrushes have exactly the same size and shape as the bottlebrush that only has one drug, but now they have a distribution of two, three, or however many drugs you want within them,” Johnson says.

In this study, the researchers first tested particles carrying just one drug: bortezomib, which is used to treat multiple myeloma, a cancer that affects a type of B cells known as plasma cells.

Bortezomib is a proteasome inhibitor, a type of drug that prevents cancer cells from breaking down the excess proteins they produce.

Accumulation of these proteins eventually causes the tumour cells to die.

When bortezomib is given on its own, the drug tends accumulate in red blood cells, which have high proteasome concentrations.

However, when the researchers gave their bottlebrush prodrug version of the drug to mice, they found that the particles accumulated primarily in plasma cells because the bottlebrush structure protects the drug from being released right away, allowing it to circulate long enough to reach its target.

Using the bottlebrush particles, the researchers were also able to analyse many different drug combinations to evaluate which were the most effective.

Currently, researchers test potential drug combinations by exposing cancer cells in a lab dish to different concentrations of multiple drugs, but those results often don’t translate to patients because each drug is distributed and absorbed differently inside the human body.

“If you inject three drugs into the body, the likelihood that the correct ratio of those drugs will arrive at the cancer cell at the same time can be very low. The drugs have different properties that cause them to go to different places, and that hinders the translation of these identified synergistic drug ratios quite immensely,” Johnson says.

However, delivering all three drugs together in one particle could potentially overcome that obstacle and make it easier to deliver synergistic ratios.

Because of the ease of creating bottlebrush particles with varying concentrations of drugs, the researchers were able to compare particles carrying different ratios of bortezomib and two other drugs used to treat multiple myeloma: an immunostimulatory drug called pomalidomide, and dexamethasone, an anti-inflammatory drug.

Exposing these particles to cancer cells in a lab dish revealed combinations that were synergistic, but these combinations were different from the synergistic ratios that had been identified using drugs not bound to the bottlebrush.

“What that tells us is that whenever you are trying to develop a synergistic drug combination that you ultimately plan to administer in a nanoparticle, you should measure synergy in the context of the nanoparticle,” Johnson says. “If you measure it for the drugs alone, and then try to make a nanoparticle with that ratio, you can’t guarantee it will be as effective.”

In tests in two mouse models of multiple myeloma, the researchers found that three-drug bottlebrushes with a synergistic ratio significantly inhibited tumour growth compared to the free drugs given at the same ratio and to mixtures of three different single-drug bottlebrushes.

They also discovered that their bortezomib-only bottlebrushes were very effective at slowing tumour growth when given in higher doses.

Although it is approved for blood cancers such as multiple myeloma, bortezomib has never been approved for solid tumours due to its limited therapeutic window and bioavailability.

“We were happy to see that the bortezomib bottlebrush prodrug on its own was an excellent drug, displaying improved efficacy and safety compared to bortezomib, and that has led us to pursue trying to bring this molecule to the clinic as a next-generation proteasome inhibitor,” Johnson says. “It has completely different properties than bortezomib and gives you the ability to have a wider therapeutic index to treat cancers that bortezomib has not been used in before.”

Johnson’s lab is also working on using these particles to deliver therapeutic antibodies along with drugs, as well as combining them with larger particles that could deliver messenger RNA along with drug molecules. “The versatility of this platform gives us endless opportunities to create new combinations,” he says.

Article: Molecular bottlebrush prodrugs as mono- and triplex combination therapies for multiple myeloma

Source: Massachusetts Institute of Technology